TCR²'s gavo-cel survives a PhI test. Now it's head-first into PhII with a half-dozen partial responses
A T cell biotech has some positive results, and now that the data are out, the biotech is moving forward on its next steps.
TCR² Therapeutics teased results from the Phase I portion of an ongoing Phase I/II study Tuesday, going on a conference call Wednesday to dive more into the details of what ended up happening. The company’s drug candidate, gavo-cel, is being investigated in solid tumors expressing mesothelin, a protein that has been examined as a biomarker in other T cell therapies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.